Company ProfilePremium

Nuheara Limited

Company Profile Analysis

Ticker: NUH.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nuheara Limited - Company showcase

Year Founded & Workforce

2015

22 Employees

Nuheara Limited logo

Nuheara Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Nuheara Limited Overview

FieldFormer listed entityCurrent operating business
Legal nameNuheara Limited (In Liquidation)Orecchio Pty Ltd, trading as Nuheara
Company numberACN 125 167 133ACN 684 518 723
Status (Oct 2026)In liquidation since 19 June 2025. KPMG liquidators targeted finalisation on or before 30 September 2026; no public confirmation of finalisation was locatedPrivate company operating the Nuheara brand, website and product range
Websitehttp://www.nuheara.com (now operated by Orecchio)www.nuheara.com (footer reads "©2025 Orecchio Pty Ltd T/A Nuheara")
CountryAustraliaAustralia
Exchange / tickerASX: NUH (suspended 1 March 2024; CHESS approval suspended 7 August 2024; subsequently removed from the official list); US OTC: NUHRFNot listed

Core identifiers (former listed entity)

FieldDetailSource
Former namesWild Acre Metals Limited (the ASX shell Nuheara reverse-took-over in 2016)ChannelNews, Aug 2024
Founding year (operating business)2015 (Nuheara founded by Justin Miller and David Cannington)Craft.co profile; NewsWire, Aug 2024
Incorporation (listed shell)2007 (ACN 125 167 133 era registration); Western Australia governing law used in DOCAROIC.ai profile; VA Supp. Report
Incorporation jurisdictionAustralia (Corporations Act 2001)KPMG reports
Headquarters (historical)190 Aberdeen Street, Northbridge, WA 6003. Vacated during administration to cut overheadsNuheara ASX releases 2023; VA Supp. Report
ASX listing2016, via reverse takeover of Wild Acre MetalsChannelNews, Aug 2024
ISIN / CUSIP——
Fiscal year end30 June4E filings FY2018–FY2023
Employees22 at administration (Aug 2024), including a US sales representative; 14 at completion of the sale to Orecchio (Mar 2025), all of whom accepted employment with Orecchio. A 3-year trend was not publicly disclosedAudiology Worldnews, Aug 2024; Liquidator's Report
AuditorWalker Wayland (independent reviewer of the H1 FY2021 half-year report).H1 FY2021 report
Market capitalisation (current)Nil equity value. Shareholders received a liquidator's declaration on 24 June 2025 under s104-145 of the Income Tax Assessment Act 1997, which allows a capital loss to be claimed on shares. Last reported market capitalisation was about A$21m around the August 2024 administrationKPMG creditor portal; NewsWire, Aug 2024
Administrators / liquidatorsMartin Jones, Matthew Woods (and Clint Joseph as administrator) of KPMG PerthKPMG creditor portal

Nuheara was a Perth-based hearing-technology company that tried to merge two categories: consumer true-wireless earbuds and medical-grade hearing assistance. Its proprietary Ear ID personalisation, its hybrid active noise cancellation and its "World Blend" / speech-in-noise controls powered the IQbuds family. They also powered the HP Hearing PRO, which in 2022 became the first product cleared through the FDA 510(k) pathway under the new self-fitting OTC hearing aid product code (QUH).

Nuheara's opportunity was the 2022 US OTC hearing-aid rule. Its weakness was chronic under-scale. Revenue peaked at A$12.6m in FY2021 on a one-off HP OEM order, then fell to A$1.9m by FY2023, while annual losses of A$7–14m were funded by repeated equity raises. Its decision to depend on Realtek for a next-generation single-chip design made its largest shareholder also its sole secured creditor and critical supplier. That concentration proved fatal. The brand and IP now survive inside a privately funded shareholder vehicle, Orecchio Pty Ltd.


What the company did

Nuheara designed, developed and commercialised multi-functional "hearables": wireless earbuds that combine audio streaming and calls with hearing enhancement, noise control and personalised sound. Over time the products were regulated as medical devices in key markets. The administrators described the group as specialising in innovative over-the-counter earbuds offering enhanced hearing and noise reduction, selling mainly in Australia, the United States and Canada (VA Supp. Report, Feb 2025).

Company self-description (paraphrased from Nuheara's boilerplate in FY2023 releases): Nuheara described itself as a global pioneer in hearable products with proprietary personalised hearing technology. It noted that its third-generation IQbuds² MAX (2020) was recognised by TIME as a Best Invention. It said its products were sold direct-to-consumer and through retail, addressing demand from people with mild to moderate hearing loss.

Independent characterisation: Nuheara was a sub-scale, fabless device designer with outsourced manufacturing. It sat between consumer electronics (crowded and low-margin) and hearing healthcare (regulated, dominated by five incumbents). Its intellectual property was mainly software and signal-processing know-how: Ear ID self-fitting, noise control and fitting algorithms. Its hardware relied on third-party chipsets, with Realtek as the strategic chipset partner from May 2022.

Business and revenue model

Revenue streamDescriptionEvidence
Branded product sales (DTC)IQbuds² MAX, IQstream TV, Bluetooth Transmitter and accessories sold via nuheara.comCompany website; FY2021 annual report commentary on record DTC sales
Retail / channel salesUS retailers including Best Buy, Crutchfield, Amazon and Target.com (from Feb 2023); Australian channels including NDIS-funded purchasesASX release 28 Feb 2023; NDIS registration coverage
OEM / co-brand manufactureHP-branded products made by Nuheara under a three-year manufacturing and supply agreement with HP Inc. (announced in the Dec 2020 quarter). This included the HP Hearing PRO OTC hearing aidQuarterly report Q2 FY2021; H1 FY2022 report (OEM income of A$3.77m in H1 FY2021)
Licensing / royaltyContemplated under the Realtek Commercial and Royalty Agreement (an MOU dated 17 May 2022). The agreement was never executedVA Supp. Report; NewsWire Aug 2024
Subscription / servicesNone disclosed—

The product/service/subscription/licensing mix by percentage was not publicly disclosed for any year. The only quantified split is H1 FY2021: OEM income of A$3,772,274 within A$6,909,566 of half-year revenue, about 55% (H1 FY2022 report comparative).

Value-chain position

Nuheara sat at the design, software and brand layer. It specified hardware, developed firmware and apps (Ear ID, IQbuds app, HP Hearing app), managed regulatory clearances (FDA 510(k) K221064) and ran brand and channel management. Manufacturing was outsourced. The administrators' reports name Salutica Allied Solutions Sdn Bhd (Malaysia) as a counterparty with debtor and prepayment balances and a counter-claim, which is consistent with a contract-manufacturing relationship. Salutica's exact role is not stated in the documents reviewed. Chipsets came from third parties, with Realtek Semiconductor (Taiwan) both a supplier and the next-generation chip development partner.

Customer types and end-markets

Customer typeEnd-market
Consumers with mild-to-moderate hearing lossUS OTC hearing aids (post-Oct 2022 FDA rule); Australian assistive listening
Consumers wanting situational hearing help (TV, restaurants, work)Assistive listening devices / "hearing enhancement" consumer electronics
Neurodivergent users / auditory processing needsAssistive audio (marketed on Nuheara's "Auditory Processing" page)
NDIS participants (Australia)Disability-funded assistive technology
OEM partner (HP Inc.)Co-branded hearing products for the US market
RetailersBest Buy, Crutchfield, Amazon, Target.com (US)

Strategy

Stated strategy (last listed period)

Nuheara's late-stage strategy had three main themes, paraphrased from FY2023–2024 releases:

  1. Win the US OTC hearing-aid category. Use the first-mover FDA self-fitting clearance and the HP brand to build US retail distribution (Best Buy, Crutchfield, Amazon, Target.com). The June 2023 A$4.4m placement was earmarked to accelerate this.

  2. Leapfrog on silicon. Build a next-generation medical-grade device on a single Realtek chip, aiming for smaller size and performance competitive with far costlier products from the five global hearing-aid makers (Miller, as reported by ChannelNews, Aug 2024).

  3. Reach a strategic outcome. From 9 April 2024, a strategic review with Azure Capital pursued M&A while cutting investment in production and marketing to reduce external capital needs (ASX 22 May 2024).

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeOwnerOutcome
Aug–Oct 2024Sale process via Azure Capital (15 expressions of interest)AdministratorsOnly one non-binding offer, for patents only, received 16 Sep 2024; no buyer would proceed without a Realtek supply agreement
Nov 2024 onwardVA Loan Funding of about A$250k a month from the shareholder committeeFarjoy, Fiago and othersKept the business trading through administration
7 Feb 2025Shareholder-committee DOCA proposed via Orecchio SPV (initially up to 10c/$ for unsecured creditors)OrecchioRevised several times
12–13 Mar 2025Revised Orecchio DOCA; total claims estimated at A$6.97mOrecchioApproved 17 Mar 2025
Mar 2025 onwardOrecchio continues to trade the Nuheara brand (IQbuds² MAX, IQstream TV, Bluetooth Transmitter, spare parts)OrecchioWebsite updated Aug 2025
By 30 Jun 2026Contingent "uplift" of up to 20c/$ extra to former creditors on sale of the business, or as Orecchio's performance allows after return of debt and capitalOrecchio / TrustOutcome not publicly disclosed

Nuheara Limited ran no strategic initiatives after 7 August 2024; control passed to the administrators. Relevant initiatives since then:

ESG commitments, transformation programmes and medium-term financial targets: none disclosed by either entity.

Products & Services

All products sat within the single hearing/hearables business. Prices are as disclosed in sources. Blank or "n/d" means not disclosed.

Commentary: Nuheara's portfolio was narrow. In practice it was one core earbud platform at a time, plus a TV accessory. The HP Hearing PRO was a re-skinned, FDA-cleared version of the Nuheara platform rather than a separate technology. Without the Realtek chip, the group had no funded next-generation product, and the administrators said this was why prospective acquirers would not bid (VA Supp. Report, s6.2).

Product Portfolio

ProductDescription / key capabilitiesTarget customerLaunch / latest versionPricingStatus

IQbuds (1st gen)

Wireless earbuds with hearing augmentation and noise control; flagship launch product

Early-adopter consumers with situational hearing difficulty

2,016—

Discontinued

IQbuds BOOST

Second generation; introduced Ear ID personalised hearing profile

Mild-to-moderate hearing difficulty

c.2018 (customer reviews on website reference BOOST with IQstream TV)

—

Discontinued; legacy pairing with IQstream TV

IQbuds² MAX

Third-generation flagship: Ear ID personalisation, hybrid active noise cancellation, Speech in Noise Control, directional Focus, World Blend, high-fidelity streaming

Consumers wanting hearing help plus premium audio

2020 (TIME Best Inventions 2020)

n/d in sources reviewed

Still listed by Orecchio on nuheara.com

IQbuds² PRO

FDA-registered wireless hearing aid variant extending the low-cost line

US consumers with hearing loss

c.2021

—

Legacy

HP Hearing PRO

Self-fitting OTC hearing aid in earbud form; Ear ID self-fitting via HP Hearing app; hybrid ANC (described as the first FDA-cleared self-fitting OTC aid with hybrid ANC); Bluetooth streaming and calls; FDA 510(k) K221064 under code QUH (21 CFR 874.3325 and 800.30)

US adults with perceived mild-to-moderate hearing loss

Cleared late 2022; launched CES Jan 2023; mass production Feb 2023

US$699

Status under Orecchio not publicly disclosed; HP licence status unknown

IQstream TV

Low-latency smart TV box streaming personalised stereo TV audio to IQbuds; per-user volume control via iOS/Android app; marketed as a "soundbar for your ears"

Older adults / households with TV-hearing conflict

c.2019–2020; relaunch promoted via Indiegogo bundle in 2023

—

Listed on nuheara.com

Bluetooth Transmitter

Connects IQbuds to non-Bluetooth sources (in-flight entertainment, stereos)

IQbuds users

——

Listed

Accessories and spare parts

Charging cases, ear tips, soundport meshes

Existing users

Ongoing

—

Listed

Ear ID (software / technology)

Self-fitting hearing-profile process; nuheara.com also hosts an NAL (National Acoustic Laboratories) hearing check

Embedded in all hearing products

Since c.2018; FDA-cleared within HP Hearing PRO

Bundled

Core IP, now owned by Orecchio

Next-generation single-chip hearing device (Realtek)

Planned medical-grade device on a single Realtek chip, intended to match or exceed premium hearing-aid performance at lower size and cost

OTC and broader hearing-aid market

In development 2022–2024; never launched

—

Halted; the Realtek commercial/royalty agreement was never executed

Financial Narrative

Income statement

Sources: FY2019, FY2020, FY2021 and FY2023 Appendix 4E reports (FY2022 figures from FY2023 4E comparatives); Kalkine and TipRanks aggregator data; Craft.co. FY2022 and FY2023 EPS are on a post-share-consolidation basis. The FY2023 4E restates FY2022 EPS at −15.56 cents against a pre-consolidation share count of about 1.72 billion at 30 June 2021. The consolidation ratio (implied around 1-for-20) was not directly verified.

Half-year EBITDA (the only EBITDA disclosures found, A$ millions):

Margins and growth

Gross, operating and EBITDA margins for full years are not publicly disclosed in the sources reviewed. Revenue CAGR from FY2019 to FY2023 on the 4E basis was about −19% a year (A$4.48m to A$1.93m). From the FY2021 peak to FY2023, revenue fell about 85%.

Balance sheet

Net tangible assets per share (cents, 4E): 0.74 at 30 June 2023 versus −2.66 at 30 June 2022 (FY2023 4E). Kalkine shows net cash of A$2.32m at FY2023, while Stoxray shows net debt of A$0.645m, a discrepancy that probably reflects treatment of convertible notes and lease liabilities.

Known debt at failure: Realtek A$2.5m secured convertible note (maturing 7 September 2024). Realtek's claimed secured debt was A$2,685,861.81 as at March 2025 (FCAFC 178, para 13). The administrators' liquidation statement of position recorded A$2.568m owed to the secured creditor (VA Supp. Report).

Cash flow: notes and sources

Source: TipRanks/Kalkine cash flow data (TipRanks labels columns December but the values reconcile to June fiscal year-end cash balances); FY2021 and FY2023 4E. Investing outflows mainly reflect capitalised development and intellectual property ("Payments to Acquire Intellectual Property" per the June 2023 quarterly).

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be computed reliably from the disclosures located. They are not publicly disclosed in the reviewed sources. All return metrics would have been deeply negative given persistent losses.

Commentary on trends, inflections and drivers

FY2019–FY2020: pre-scale burn: Revenue was flat at about A$4.4–4.5m (4E basis) while net losses of A$10–12m a year were funded by equity and, from January 2020, the Lind convertible facility. Product-led revenue never reached a scale that could carry the R&D and marketing cost base.

FY2021: the false dawn: The IQbuds² MAX launch and the HP OEM programme produced a record A$12.6m. H1 FY2021 recorded positive EBITDA of A$1.48m and near-breakeven operating cash flow of −A$86k (H1 FY2021 report). This was the only period in Nuheara's listed life with positive EBITDA. It depended on a lumpy OEM order rather than recurring consumer demand.

FY2022: the cliff: With OEM revenue gone, revenue fell 69%. The net loss widened to A$14.3m, the largest in the company's history, and cash fell to A$0.44m at 30 June 2022. This made the company dependent on strategic capital. The Realtek MOU (May 2022) and Realtek's investment filled the gap but tied the company to one counterparty.

FY2023: regulatory win, commercial miss: Despite the world-first FDA self-fitting OTC clearance, FY2023 revenue halved again to A$1.93m. The company attributed part of the fall to strong prior-year second-half revenue, and also recorded inventory write-downs on Nuheara-branded stock. Cash rose to A$2.32m only because A$10.8m was raised. The June 2023 quarterly cited over A$1m in invoiced OTC hearing-aid sales to date, which was too small to change the trajectory.

FY2024: reporting failure and collapse: No accounts were lodged. Suspension (1 March 2024), a strategic review (April), a A$1.85m raise (April), cost cuts (May) and administration (August) followed. The administrators collected a FY2024 R&D tax rebate of A$840k (net of ATO offsets) during administration (VA Supp. Report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionRoleStatus (Oct 2026)

Nuheara Limited

Australia

Parent; ASX-listed; employing and trading entity

In liquidation (from 19 Jun 2025)

Nuheara IP Pty Ltd (ACN 605 704 096)

Australia

Owned the group's intellectual property

Subject to DOCA; the DOCA included a clause on control of this entity. Its post-DOCA ownership was not confirmed in the documents reviewed

Terrace Gold Pty Ltd (ACN 072 608 952)

Australia

Primarily dormant (legacy mining-era entity)

Subject to DOCA; post-DOCA status not confirmed

Nuheara, Inc.

USA

US operations / sales

Not in administration; status not publicly disclosed

Other subsidiaries (total of six controlled)

Reported to include UK, Canada and Netherlands entities

Regional distribution

Not in administration; status not publicly disclosed

Orecchio Pty Ltd (ACN 684 518 723)

Australia

SPV nominated by the shareholder committee; bought the business and assets

Operating Nuheara business; has granted security to its shareholders Farjoy Pty Ltd and Fiago Pty Ltd

Revenue by Segment

ChannelFY2019FY2020FY2021FY2022FY2023

Total revenue from ordinary activities (AUD Mn)

4.484.4412.623.871.93

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (Half-Yearly)

ChannelH1 FY2021H1 FY2022

OEM income (AUD Mn)

3.77—

Other / branded revenue (AUD Mn)

3.14—

Total half-year revenue (AUD Mn)

6.912.97

Income Statement and Per-Share Data

MetricFY2019FY2020FY2021FY2022FY2023

Revenue from ordinary activities per 4E (AUD Mn)

4.484.4412.623.871.93

Sales revenue per aggregator (AUD Mn)

2.221.7410.743.871.93

Cost of revenue per aggregator (AUD Mn)

1.8511.218.777.582.88

Gross profit per Craft.co (AUD Mn)

————0.80

Net loss after tax attributable to members (AUD Mn)

-10.03-11.69-7.20-14.34-11.15

Total comprehensive loss per aggregator (AUD Mn)

-10.03-11.69-7.89-14.80-12.62

Basic and diluted EPS (A$ cents)

-1.09-1.14-0.46-15.56-7.41

Dividends per share (A$ cents)

00000

Income Statement

MetricH1 FY2020H1 FY2021H1 FY2022

EBITDA (AUD Mn)

-3.621.48-3.68

Half-year revenue (AUD Mn)

1.376.912.97

Half-year net loss (AUD Mn)

-5.73-0.84-6.01

Margin Analysis (%)

MetricFY2019FY2020FY2021FY2022FY2023

Net margin on 4E revenue (%)

-224-263-57-371-578

Revenue growth on 4E basis (%)

-15-1185-69-50

Gross margin per Craft.co (%)

————42

Key Financials

MetricFY2019FY2020FY2021FY2022FY2023

Cash and equivalents (AUD Mn)

3.224.437.280.442.32

Net tangible assets per aggregator (AUD Mn)

10.115.4711.79-2.644.43

Net receivables per aggregator (AUD Mn)

0.671.571.620.553.26

Net debt per Kalkine (AUD Mn)

-0.68-1.89-7.280.89-2.32

Cash Flow

MetricFY2019FY2020FY2021FY2022FY2023

Operating cash flow (AUD Mn)

-6.50-5.43-4.07-9.30-7.48

Investing cash flow (AUD Mn)

-3.91-3.53-3.82-4.55-2.82

Financing cash flow (AUD Mn)

5.2910.1810.746.9812.15

Free cash flow (AUD Mn)

-6.61-8.97-8.03-13.85-10.36

Net capital raised, net of costs, per 4E (AUD Mn)

——10.95—10.83

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Margin Analysis (%) (2)

RatioFY2019FY2020FY2021FY2022FY2023

Cash burn cover: year-end cash ÷ annual FCF burn (years)

0.490.490.910.030.22

FCF ÷ revenue on 4E basis (%)

-148-202-64-358-536

Revenue by Region

RegionFY2021FY2022FY2023

Total revenue from ordinary activities (AUD Mn)

12.623.871.93

Region Overview

RegionChannel exposureDirection (qualitative)Evidence

United States

HP OEM (FY2021), HP Hearing PRO OTC retail (Best Buy, Crutchfield, Amazon, Target.com), DTC

Strategic growth focus from 2022. US-based CEO John Luna appointed for the OTC launch; June 2023 placement explicitly aimed at US commercialisation

ASX releases 2022–2023

Australia

DTC, NDIS-funded channel

Home market; NDIS registration widened access

The Sentiment; company website NDIS page

UK

Distributor Puretone

Minor; a UK tender/contract via Puretone referenced in FY2021

Q2 FY2021 quarterly

Canada, Netherlands, Hong Kong, NZ

Online / distributors

Minor

Website region selector; ROIC.ai subsidiary list

Data Point Details

Data pointValueSource

Placement price, Dec 2021 (pre-consolidation)

A$0.016

H1 FY2022 report

Placement price, Jun 2023 (post-consolidation)

A$0.145

ASX placement release

Last price before suspension

A$0.08 (27 Feb 2024)

Stoxray

Market capitalisation around administration

About A$21m

NewsWire / Market Index, Aug 2024

Share price change, calendar 2023

-41.03%

ChannelNews

Share price change, 2024 to administration

about -30%

NewsWire / ChannelNews

Current equity value

Nil (s104-145 declaration, 24 Jun 2025)

KPMG

Capital Markets

ItemDetail

Analyst consensus

None identified (no sell-side coverage found)

Dividend history / policy

No dividend ever paid

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile at failure

Single A$2.5m secured convertible note maturing 7 Sep 2024 (Realtek); VA loan funding from shareholders after appointment (repaid by DOCA: A$1,633,277 loan repayment in the deed period)

Creditor Class Details

Creditor classOutcome

Secured (Realtek)

A$500,000 (24 Mar 2025) against a claimed A$2.69m; security extinguished; failed appeals; adverse costs

Priority employees

100c/$ (A$134,419.17 paid 27 Jun 2025) or transferred to Orecchio

Unsecured (trust beneficiaries)

Estimated initial dividend of about 47.6c/$, held back pending appeal in Sep 2025, plus a contingent uplift of up to 20c/$ by 30 Jun 2026. Trust balance A$2,703,459 at 15 Sep 2025

Intercompany creditors

Excluded (removing about 76% of claims by value)

Analyst Conclusions

Guidance and consensus

No management guidance or consensus exists. Nuheara Limited is a liquidation shell and Orecchio is private. The only forward markers in the public record are (a) the contingent uplift deadline of 30 June 2026 for former creditors and (b) the liquidators' target to finalise the liquidation by 30 September 2026.

Bull case (for the Nuheara brand under Orecchio)

  1. Clean slate: The DOCA removed all pre-administration claims, and secured debt was settled for A$500k. Orecchio carries the IP and FDA clearance without the listed company's burn-heavy overhead.

  2. Committed owners: The shareholder committee put in about A$5.84m through the DOCA plus monthly funding, a sign of conviction and capacity to keep the business running.

  3. Category tailwinds: OTC hearing aids remain a growth category, with forecasts as high as a 15% CAGR, and the company's FDA precedent and installed base could support licensing or a trade sale.

Bear case

  1. Commoditised value proposition: Apple's 2024 FDA-authorised hearing-aid software in AirPods Pro, along with incumbent OTC brands, erodes the earbud-plus-hearing-aid niche.

  2. No next-generation product: Without the Realtek single-chip platform, the product line rests on IQbuds² MAX technology launched in 2020.

  3. Track record: Five audited years of losses (A$54m cumulative FY2019–FY2023), revenue down 85% from its peak, and buyers in 2024 unwilling to pay more than a nominal sum without a supply agreement.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Distribution of the initial ~47.6c/$ dividend from the Creditors' Trust, now that High Court proceedings ended 12 Mar 2026Final creditor outcome
Whether the 20c/$ uplift was triggered by 30 Jun 2026Indicates Orecchio's commercial performance or a sale
Finalisation and deregistration of Nuheara LimitedFormal end of the listed entity
Any ASIC action from the liquidators' s533 reportingGovernance and legal closure
Orecchio product or partnership announcements (HP licence status, new chip partner)Viability of the brand
Any trade sale of Orecchio / Nuheara IPValue realisation for the shareholder syndicate

Concluding analyst verdict

Nuheara is a cautionary case of a technically credible, under-capitalised device company whose regulatory win came too late and was spread too thin to become a durable business. In the hearing-technology segment it had real firsts. Its HP Hearing PRO became the first 510(k)-cleared self-fitting OTC hearing aid in 2022, and its products won mainstream design recognition. Commercially, though, the company never found a repeatable revenue engine. Its one profitable half-year (H1 FY2021) rested on an HP OEM order that did not recur. Revenue then fell from A$12.6m to A$1.9m in two years while annual cash burn stayed at A$8–14m.

To bridge that gap, management concentrated strategic, supply and financing risk in one counterparty. Realtek became, simultaneously, the largest shareholder, the sole secured creditor and the gatekeeper to the next-generation chip. When the commercial and royalty agreement was not signed and the A$2.5m note fell due, the company had no fallback. The administrators concluded that no buyer would pay meaningful value without that supply agreement, which makes clear that Nuheara's IP was worth little without its partner.

The restructuring was well run for creditors and employees: priority staff were paid in full, an initial unsecured dividend of about 47.6c/$ was estimated, and Realtek's challenges failed at every court level. For equity holders, however, the outcome was total loss.

The surviving business, Orecchio Pty Ltd trading as Nuheara, is a privately funded bet that a leaner owner can monetise the brand, FDA precedent and installed base. With Apple and the hearing-aid oligopoly now competing directly in OTC, and no disclosed next-generation product, its prospects are speculative. Verdict: listed equity is extinguished and uninvestable. The successor business is a high-risk niche asset whose most plausible value-realisation path is a licensing deal or trade sale rather than independent scale.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / notesSource

Justin Paul Miller

Co-founder, Managing Director and CEO

Co-founded Nuheara 2015; Executive Chair until Feb 2020, then MD/CEO; took a 60% salary cut from 16 Apr 2024 during the strategic review

VA Supp. Report; ASX release 22 May 2024

Cheryl Lynn Edwardes

Non-Executive Chair

—

H1 FY2020 release; VA Supp. Report

David Buckingham

Non-Executive Director

—

VA Supp. Report; Craft.co

Kathryn Sue Giudes

Non-Executive Director

—

VA Supp. Report

Yean-Shao Liu

Non-Executive Director

Appointed during the Realtek relationship. Affiliation with Realtek is likely given timing but was not confirmed in the documents reviewed

VA Supp. Report

Executive Leadership Team

NameRolePeriodSource

David Cannington

Co-founder

—

NewsWire Aug 2024

John Luna

US-based CEO (Nuheara US / OTC business)

c.2022–2023

HearingTracker 2022; ASX release Feb 2023

Catherine Morgan

Senior executive appointed in the Q4 FY2023 restructure (title not stated in the extract reviewed)

From mid-2023

June 2023 quarterly

Alan Davis

Chief Product Officer

—

Craft.co

Jean-Marie Rudd

Chief Financial Officer

—

Craft.co

Gillian Jowett-Blinman; Ivan Kelly

Named as contacts for the purchaser after completion

Mar 2025

KPMG circular 21 Mar 2025

Governance Overview

AttributeAssessment

Board size at failure

5

Independence

3 of 5 likely independent (Edwardes, Buckingham, Giudes). Miller was executive; Liu was probably investor-associated

Chair/CEO separation

Yes, separated since Feb 2020

Gender diversity

2 of 5 directors female (Edwardes, Giudes)

Major Shareholders

HolderDescriptionStake

Realtek Semiconductor Corporation

Largest shareholder, largest creditor and only secured creditor

% not publicly disclosed in sources reviewed

Farjoy Pty Ltd

Among the three largest holders (Jun 2023); funded administration; Orecchio shareholder / secured lender

% not disclosed

Salter Brothers

Among the three largest holders (Jun 2023)

% not disclosed

Fiago Construction Pty Ltd / Fiago Pty Ltd

Named "Major Shareholder"; Orecchio shareholder / secured lender

% not disclosed

Mr Xuan Khoa Pham

Named "Major Shareholder" by administrators

% not disclosed

Competitive Landscape

Key Competitors

CompetitorSegment overlapRelative positioning vs Nuheara

Sonova (Phonak; Sennheiser All-Day Clear OTC, launched US June 2023)

Prescription and OTC hearing aids

Global leader; one market study puts its audiology-devices share at over 25% (2024)

Demant (Oticon, Philips Hearing licence)

Prescription hearing aids

Big Five incumbent; estimates underlying market growth at 4–6% a year

WS Audiology (Signia, Widex; Sony OTC partnership)

Prescription and OTC

Big Five; partnered with Sony for consumer OTC

GN Store Nord (ReSound, Jabra Enhance)

Prescription and OTC / DTC

Big Five; GN Hearing revenue reported as DKK 7,214m in 2025 (Ken Research)

Starkey

Prescription, some OTC

Private US Big Five member; about 4% global share (Ivey Business Review)

Apple (AirPods Pro hearing-aid feature)

OTC hearing-aid software in mass-market earbuds

FDA authorised as the first OTC hearing-aid software device in 2024. Arguably the most damaging threat to Nuheara's earbud-plus-hearing-aid proposition

Sony (CRE-series OTC aids)

OTC

Consumer-electronics brand with WS Audiology technology; US$999 class pricing at Nuheara's launch

Lexie / hearX (Bose-powered OTC)

OTC self-fitting

Direct OTC rival; around US$999 at Nuheara's launch

Eargo

DTC / OTC invisible hearing aids

DTC rival

MDHearing, Lucid Hearing, SoundWave Hearing

Low-cost OTC / PSAP

Price competition below US$699

Jabra, Samsung, Bose (consumer hearables)

Earbuds with hearing-enhancement features

Large-scale consumer competition

Peer Comparison FY2023

MetricNuheara FY2023GN Hearing 2025

Revenue (local currency M)

1.937,214

Currency

AUD

DKK

Revenue growth (%)

-50—

Net margin (%)

-578—

R&D intensity proxy (%)

146—

Recent Developments

The register is therefore extended back to February 2025 to capture the restructuring that defines the current entity.

Company Snapshot

22

Employees

2015

Founded

Northbridge, Australia

Headquarters

SWOT Analysis

Strengths

  • Regulatory first-mover: HP Hearing PRO was the first device cleared via 510(k) under code QUH (K221064), 2022
  • Recognised product design: IQbuds² MAX named a TIME Best Invention in 2020; multiple CES Innovation Awards
  • Shown ability to win a tier-one OEM: Three-year HP manufacturing and supply agreement; A$3.77m of OEM income in H1 FY2021
  • Proven peak of operating leverage: H1 FY2021 EBITDA of +A$1.48m on A$6.9m revenue
  • Committed shareholder base: Shareholder committee funded about A$250k a month through administration and contributed A$5.84m to the DOCA (Liquidator's Report)
  • Brand survival: Orecchio still trades the Nuheara brand and products in 2025 (website footer)

Weaknesses

  • Chronic losses: Net losses of A$7.2–14.3m every year FY2019–FY2023
  • Revenue collapse after OEM: Revenue fell from A$12.62m (FY2021) to A$1.93m (FY2023)
  • Severe cash fragility: Cash of A$0.44m at 30 Jun 2022, less than two weeks of FY2022 free-cash-flow burn
  • Counterparty concentration: Realtek was largest shareholder, largest creditor, sole secured creditor and critical supplier (FCAFC 178, para 2)
  • Reporting failure: Suspended 1 Mar 2024 for not lodging a periodic report
  • Inventory risk: Inventory written down to net realisable value in FY2022 (A$713,901) and FY2023

Opportunities

  • OTC category growth: One forecast has OTC hearing aids at US$5.6bn by 2033, a 15.3% CAGR (Ken Research)
  • Clean balance sheet: DOCA released all pre-administration claims; administrators stated the group would be solvent on effectuation
  • Monetising the FDA clearance: K221064 is a valuable precedent asset for licensees or acquirers
  • Assistive TV listening niche: IQstream TV still promoted as a multi-listener TV solution
  • Australian NDIS channel: Funded assistive-technology demand
  • Trade sale: DOCA uplift mechanism anticipates a possible sale of the business

Threats

  • Big-tech substitution: Apple's FDA-authorised OTC hearing-aid software (2024)
  • Incumbent OTC entry: Sennheiser All-Day Clear (Sonova, June 2023); Jabra Enhance (GN); Sony/WSA
  • Chip-supply dependence: Breakdown with Realtek ended the next-generation roadmap
  • Price compression: Rivals priced at US$999 at launch were followed by sub-US$500 OTC options
  • Funding risk at Orecchio: Orecchio has granted security to its shareholders, Farjoy and Fiago (FCAFC 178, para 8), showing reliance on shareholder debt
  • Residual legal and regulatory scrutiny: Liquidators investigating whether directors met disclosure obligations about a large unsecured creditor debt (Liquidator's Report)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Feb 2025Shareholder committee lodges DOCA proposal via OrecchioFirst viable alternative to liquidation
17 Feb 2025VA Supp. Report recommends the Orecchio DOCA; s442C application filedAdministrators back the shareholder rescue
21 Feb 2025Federal Court grants leave to sell Realtek-secured assets ([2025] FCA 267)Removes Realtek's veto
25 Feb 2025Reconvened second meeting and eligible-employee meeting heldVote deferred as rival proposals emerge
7 Mar 2025Second Supplementary Report compares Orecchio and Realtek DOCAsCompetitive DOCA process
8 Mar 2025Realtek submits rival DOCALargest shareholder tries to take the business
12–13 Mar 2025Orecchio revises DOCA; estimated total claims A$6.97mBetter terms for unsecured creditors
13 Mar 2025Court varies s442C leave and refuses Realtek injunction ([2025] FCA 276); sale agreements executed with both bidders conditionallyClears path for creditor vote
17 Mar 2025Creditors approve Orecchio DOCA at third reconvened meetingDecides the company's future
20 Mar 2025DOCA and BSPA executed; business sold to OrecchioOperating business leaves the listed entity
24 Mar 2025A$500,000 paid to Realtek; security extinguished under s442C(7)Realtek's secured position ends
c.Mar 2025ASX removal from the official list under LR 17.12 recorded by an aggregator (date shown as 2 Mar 2025, which conflicts with the 1 Mar 2024 suspension date; removal date unconfirmed)End of listing
10 Apr 2025Realtek files Notice of AppealLitigation overhang on the trust fund
23 May 2025Circular on judicial application and Creditors' Trust DeedTrust mechanics finalised
16 Jun 2025Order of O'Sullivan J (Nuheara v Realtek matter)Clears DOCA completion steps
19 Jun 2025DOCA effectuated; Creditors' Trust established; Nuheara Limited into liquidationListed shell wound up
20 Jun 2025Circular to creditors on DOCA effectuationFormal notification
24 Jun 2025Liquidator's s104-145 declaration to shareholdersConfirms shares worthless for tax purposes
27 Jun 2025First and final distribution of A$134,419.17 to priority employee creditors (100c/$)Former employees paid in full
8–11 Aug 2025Liquidators apply to dismiss or stay Realtek's appeal as futileDefensive litigation
12 Aug 2025nuheara.com updated under "Orecchio Pty Ltd T/A Nuheara"Brand continues privately
18 Sep 2025Liquidator's statutory report: initial dividend of about 47.6c/$ held back pending appeal; directors' disclosure conduct under reviewCreditor-return clarity; governance flag
26 Nov 2025Full Federal Court dismisses Realtek appeal, with costs (FCAFC 178)Removes main barrier to trust distribution
4 Dec 2025Reasons for judgment publishedCourt found the damages claim hopeless and noted Realtek did not seek a stay
12 Mar 2026High Court refuses Realtek special leave, with costs ([2026] HCADisp 45)Litigation fully concluded
30 Jun 2026Deadline for contingent uplift dividend of up to 20c/$Outcome not publicly disclosed
30 Sep 2026Liquidators' target date for finalising the liquidation–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2019–FY2023): Total revenue from ordinary activities fell from AUD 4.5 Mn in FY2019 to AUD 1.9 Mn in FY2023.
Nuheara Limited — Revenue by Segment (FY2019–FY2023)
Series (AUD Mn)FY2019FY2020FY2021FY2022FY2023
Total revenue from ordinary activities4.54.412.63.91.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. KPMG Australia, Nuheara Ltd creditor portal (appointment details, communications, court documents) (kpmg.com)
  2. KPMG, Voluntary Administrators' Report, 10 December 2024
  3. KPMG, Voluntary Administrators' Supplementary Report, 17 February 2025
  4. KPMG, Voluntary Administrators' Second Supplementary Report, 7 March 2025, and Addendum, 13 March 2025
  5. KPMG, Circulars to Creditors, 13, 14, 16 and 21 March 2025 and 20 June 2025
  6. KPMG, Statutory Report by Liquidator, 18 September 2025
  7. Federal Court of Australia, *Realtek Semiconductor Corporation v Jones (Administrator), in the matter of Nuheara Limited* [2025] FCAFC 178 (judgment 26 Nov 2025; reasons 4 Dec 2025)
  8. High Court of Australia, *Realtek Semiconductor Corporation v Jones & Woods* [2026] HCADisp 45 (12 Mar 2026)
  9. Federal Court originating process WAD 254/2024 (Realtek s588FM application), 12 Sep 2024
  10. ASX Settlement notice 0916.24.08 (8 Aug 2024)
  11. Nuheara Limited Appendix 4E reports: FY2018, FY2019, FY2020, FY2021, FY2023; Half-year reports H1 FY2020, H1 FY2021, H1 FY2022; Quarterly reports Dec 2020 and Jun 2023
  12. Nuheara ASX releases: 28 Feb 2023 (Target.com / HP Hearing PRO shipment); Jun 2023 placement; 22 May 2024 strategic review update
  13. nuheara.com homepage (Orecchio Pty Ltd T/A Nuheara footer, accessed Oct 2026)
  14. HearingTracker, MedTech Dive, Hearing Review, Hearing Health Matters (HP Hearing PRO FDA clearance and launch, 2022–2023)
  15. ChannelNews (Aug 2024); Business News Australia (Aug 2024); NewsWire / AMR Times (Aug 2024); Insolvency Insider (Aug 2024); Audiology Worldnews (2024); Seniors Discount Club (Aug 2024); The Sentiment
  16. Delisted.com.au (Nuheara Limited)
  17. Aggregators: Kalkine, TipRanks, Craft.co, Stoxray, ROIC.ai (financial data used only where primary filings were unavailable; discrepancies noted)
  18. Market context: Ken Research (Global Hearing Aids Market 2025–2032); MarketsandMarkets (Hearing Aids Market); Global Market Insights (Audiology Devices; US OTC Hearing Aids); Ivey Business Review (Starkey)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.